Apollo BioSciences' mission is to turn the Pharmefex™ technology developed at the University of Vermont into a potent drug delivery platform for cancer treatment. Based in Burlington, Vermont, our scientists are dedicated to translating the theoretical into the usable.
We are a spinout of Apollo SRI, LLC. Apollo SRI has raised funds from the National Institutes of Health (NIH) to explore the commercialization potential of Pharmefex™. Apollo SRI is a member of Vermont Center for Emerging Technologies (VCET), and we work closely with the University of Vermont.